Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 10, 2026, 1:50 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 2,141 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Depressive Disorder, NOS Clear all
Completed Phase 4 Interventional

Escitalopram Treatment of Major Depression in Patients With Temporal Lobe Epilepsy

NCT00595699
View directory record Official record
Conditions
Major Depression, Temporal Lobe Epilepsy
Interventions
escitalopram, placebo
Drug
Lead sponsor
Conrad, Erich J., M.D.
Other
Eligibility
18 Years to 65 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Jul 17, 2011 · Synced Sep 10, 2026, 1:50 PM EDT
Recruiting No phase listed Observational

Ketamine Treatment Plans for Chronic Conditions

NCT06038409
View directory record Official record
Conditions
Chronic Pain, Depressive Disorder, Anxiety Disorders, Chronic Disease
Interventions
Ketamine
Drug
Lead sponsor
RIVER Foundation
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
1
States / cities
Helena, Montana
Source: ClinicalTrials.gov public record
Updated Nov 25, 2024 · Synced Sep 10, 2026, 1:50 PM EDT
Completed Phase 3 Interventional

Efficacy and Safety of SR58611A in Patients With Major Depressive Disorder (SIRIUS)

NCT00385307
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
amibegron (SR58611A)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 65 Years
Enrollment
680 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 24, 2009 · Synced Sep 10, 2026, 1:50 PM EDT
Recruiting Not applicable Interventional

Treatment of Acute Mood Depressive Episode in Borderline Personality Disorder With rTMS

NCT04870255
View directory record Official record
Conditions
Depressive Disorder, Major, Borderline Personality Disorder
Interventions
Left Dorsolateral Prefrontal Cortex (L-DLPFC), Dorsomedial Prefrontal Cortex (DMPFC), Sham Stimulation
Device
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 80 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Sep 10, 2026, 1:50 PM EDT
Active, not recruiting Not applicable Interventional

CET- REM (Correlating ECT Response to EEG Markers)

NCT04451135
View directory record Official record
Conditions
ECT, Treatment Resistant Depression
Interventions
Electroencephalographic (EEG), Quick Inventory of Depressive Symptomatology-Self Report (QIDS-SR16), Ictal Electroencephalographic (EEG) Measurements, Post-Ictal Electroencephalographic (EEG) Suppression Measurements
Diagnostic Test
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 30, 2025 · Synced Sep 10, 2026, 1:50 PM EDT
Completed Phase 2 Interventional Results available

Double-Blind Treatment of Major Depressive Disorder With Vilazodone

NCT01742832
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Vilazodone, Citalopram
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 60 Years
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 22, 2023 · Synced Sep 10, 2026, 1:50 PM EDT
Completed Not applicable Interventional Results available

Vagal Nerve Stimulation for Treatment Resistant Major Depression

NCT04990687
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
gammaCore™
Device
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 75 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jun 30, 2024 · Synced Sep 10, 2026, 1:50 PM EDT
Completed Phase 2 Interventional Results available

Pilot Study of Duloxetine in Psychological Resilience

NCT00331799
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Duloxetine
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 1, 2013 · Synced Sep 10, 2026, 1:50 PM EDT
Completed Phase 2 Interventional Results available

Ketamine Plus Lithium in Treatment-Resistant Depression

NCT01880593
View directory record Official record
Conditions
Depression
Interventions
Lithium, Ketamine, Placebo
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
21 Years to 65 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 30, 2018 · Synced Sep 10, 2026, 1:50 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Investigational TMS Treatment for Depression

NCT03175887
View directory record Official record
Conditions
Depression, Treatment Resistant Depression
Interventions
TMS
Device
Lead sponsor
White River Junction Veterans Affairs Medical Center
Federal
Eligibility
21 Years to 70 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
White River Junction, Vermont
Source: ClinicalTrials.gov public record
Updated May 12, 2021 · Synced Sep 10, 2026, 1:50 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Effectiveness and Safety of Extended-Release (ER) Paliperidone Compared With Placebo in Delaying the Recurrence of Symptoms in Bipolar I Disorder

NCT00490971
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Olanzapine, Paliperidone ER, Placebo
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years to 65 Years
Enrollment
768 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
16
States / cities
Scottsdale, Arizona • Riverside, California • San Diego, California + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2015 · Synced Sep 10, 2026, 1:50 PM EDT
Recruiting Phase 2 Interventional

Search for Novel Transcranial Magnetic Stimulation (TMS) Targets for Mental Illness

NCT06376734
View directory record Official record
Conditions
Major Depressive Disorder, Obsessive-Compulsive Disorder, Schizophrenia, Generalized Anxiety Disorder, Mood Disorders, Psychiatric Disorder, Mental Disorder, Depression, Anxiety
Interventions
Transcranial magnetic stimulation
Device
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
2
States / cities
Sunnyvale, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Sep 10, 2026, 1:50 PM EDT
Completed Not applicable Interventional

Integrated Chronotherapy for Perinatal Depression

NCT02053649
View directory record Official record
Conditions
Depression, Major Depressive Disorder, Postpartum Depression
Interventions
Triple Chronotherapy, Usual Care
Behavioral · Other
Lead sponsor
Rhode Island Hospital
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated May 28, 2019 · Synced Sep 10, 2026, 1:50 PM EDT
Completed Not applicable Interventional

Optimizing a Just-in-time Adaptive Intervention for Suicide Safety Planning in Adolescents

NCT06665620
View directory record Official record
Conditions
Suicide, Mental Health Disorder, Anhedonia
Interventions
ViraBrite nudges
Behavioral
Lead sponsor
Ksana Health
Industry
Eligibility
13 Years to 18 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Sep 10, 2026, 1:50 PM EDT
Recruiting Not applicable Interventional

Behavioral Health Collaborative Care Model in an ICU Recovery Clinic

NCT07372586
View directory record Official record
Conditions
PICS, Anxiety, Depression - Major Depressive Disorder, Post-Traumatic Stress, PTSD, Critical Illness Recovery, Critical Illness, Collaborative Care, Behavioral Health Concerns
Interventions
Behavioral Health Collaborative Care Model
Behavioral
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Sep 10, 2026, 1:50 PM EDT
Completed Phase 3 Interventional

Open-Label Treatment With Duloxetine Hydrochloride Once-Daily Dosing for Evaluation of Stabilization Dose in Patients With Major Depression

NCT00042562
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
duloxetine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
23
States / cities
Carlsbad, California • Los Angeles, California • Stanford, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2006 · Synced Sep 10, 2026, 1:50 PM EDT
Completed Phase 3 Interventional

Risperidone and Suicidality in Major Depressive Disorder

NCT00167154
View directory record Official record
Conditions
Depression
Interventions
Risperidone and placebo comparator
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jun 9, 2021 · Synced Sep 10, 2026, 1:50 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

PAXIL CR Bioequivalence Study

NCT00749359
View directory record Official record
Conditions
Depressive Disorder
Interventions
Paxil CR
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
166 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
2
States / cities
Buffalo, New York • Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Aug 3, 2017 · Synced Sep 10, 2026, 1:50 PM EDT
Terminated Phase 4 Interventional Results available

Tianeptine for Treatment Resistant Depression

NCT04249596
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
Tianeptine Sodium
Drug
Lead sponsor
Jonathan A. Javitch, MD, PhD
Other
Eligibility
21 Years to 60 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
3
States / cities
Stanford, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Sep 10, 2026, 1:50 PM EDT
Completed Not applicable Interventional

Extended Reality Behavioral Activation: An Intervention for Major Depressive Disorder

NCT05525390
View directory record Official record
Conditions
Major Depressive Disorder, MDD, Depression
Interventions
Extended Reality-Enhanced Behavioral Activation, Traditional Behavioral Activation
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Sep 21, 2025 · Synced Sep 10, 2026, 1:50 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Novel Neural Circuit Biomarkers of Major Depression Response to CCBT

NCT03096886
View directory record Official record
Conditions
Depression, Major Depressive Disorder, Depressive Disorder, Depression, Unipolar
Interventions
Computer-Augmented Cognitive Behavioral Therapy
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 60 Years
Enrollment
132 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 4, 2024 · Synced Sep 10, 2026, 1:50 PM EDT
Recruiting Not applicable Interventional

Cognitive Rehabilitation for Veterans With MDD-related Cognitive Functioning Deficits

NCT06728774
View directory record Official record
Conditions
Major Depressive Disorder (MDD), Cognitive Dysfunction
Interventions
Motivationally Enhanced Compensatory Cognitive Training for Major Depressive Disorder (ME-CCT-MDD), Goal-focused Supportive Contact
Behavioral
Lead sponsor
Portland VA Medical Center
Federal
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jun 5, 2025 · Synced Sep 10, 2026, 1:50 PM EDT
Completed Phase 3 Interventional Results available

VA Augmentation and Switching Treatments for Improving Depression Outcomes

NCT01421342
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Switching: Bupropion-SR, Augmenting: Antidepressant + Bupropion-SR, Augmenting: Antidepressant + Aripiprazole
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
1,522 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
35
States / cities
Tuscaloosa, Alabama • Phoenix, Arizona • Tucson, Arizona + 32 more
Source: ClinicalTrials.gov public record
Updated May 28, 2018 · Synced Sep 10, 2026, 1:50 PM EDT
Enrolling by invitation Phase 3 Interventional

An Open-Label Study of Azetukalner in Major Depressive Disorder

NCT06922110
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Azetukalner
Drug
Lead sponsor
Xenon Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
69
States / cities
Phoenix, Arizona • Bryant, Arkansas • Little Rock, Arkansas + 58 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Sep 10, 2026, 1:50 PM EDT